<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Ocular Therapeutix Inc — News on 6ix</title>
    <link>https://6ix.com/company/ocular-therapeutix-inc</link>
    <description>Latest news and press releases for Ocular Therapeutix Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 28 Apr 2026 11:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/ocular-therapeutix-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a5b078dffbe2df10b36f.webp</url>
      <title>Ocular Therapeutix Inc</title>
      <link>https://6ix.com/company/ocular-therapeutix-inc</link>
    </image>
    <item>
      <title>Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026</title>
      <link>https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-to-report-first-quarter-2026-financial-results-on-may-5-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-to-report-first-quarter-2026-financial-results-on-may-5-2026</guid>
      <pubDate>Tue, 28 Apr 2026 11:00:00 GMT</pubDate>
      <description>BEDFORD, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, May 5, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the first quarter ended March 31, 2026. Conference Call and Webcast Information: Date: Tuesday, May 5, 2026 at 8:00 AM ETParticipant Dial-In (U</description>
    </item>
    <item>
      <title>Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences</title>
      <link>https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-to-participate-in-may-scientific-and-investor-conferences</link>
      <guid isPermaLink="true">https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-to-participate-in-may-scientific-and-investor-conferences</guid>
      <pubDate>Mon, 27 Apr 2026 11:00:00 GMT</pubDate>
      <description>BEDFORD, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in May 2026. Upcoming Investor Conferences: Bank of America Health Care Conference 2026:Date: Tuesday, May 12, 2026Fireside Chat: 3:40 – 4:10 PM PDTPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation</description>
    </item>
    <item>
      <title>Ocular Therapeutix™ to Host Investor Day on June 17, 2026</title>
      <link>https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-to-host-investor-day-on-june-17-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-to-host-investor-day-on-june-17-2026</guid>
      <pubDate>Wed, 22 Apr 2026 11:00:00 GMT</pubDate>
      <description>Ocular’s Investor Day will take place in New York City, with virtual access available, starting at 2:00 PM ET on Wednesday, June 17, 2026BEDFORD, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced plans to host an Investor Day on Wednesday, June 17, 2026, in New York City. Click here to register for the live event, with virtual access available, which w</description>
    </item>
    <item>
      <title>Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD</title>
      <link>https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-announces-additional-positive-week-52-data-from-landmark-sol-1-phase-3-trial-of-axpaxlitm-in-wet-amd</link>
      <guid isPermaLink="true">https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-announces-additional-positive-week-52-data-from-landmark-sol-1-phase-3-trial-of-axpaxlitm-in-wet-amd</guid>
      <pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
      <description>New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI’s unmatched durability in wet AMD with sustained disease control AXPAXLI demonstrated robust</description>
    </item>
    <item>
      <title>Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April</title>
      <link>https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-to-present-additional-sol-1-data-and-analyses-at-upcoming-scientific-conferences-in-april</link>
      <guid isPermaLink="true">https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-to-present-additional-sol-1-data-and-analyses-at-upcoming-scientific-conferences-in-april</guid>
      <pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
      <description>BEDFORD, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to</description>
    </item>
    <item>
      <title>Ocular Therapeutix™ to Participate in March Investor Conferences</title>
      <link>https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-to-participate-in-march-investor-conferences</link>
      <guid isPermaLink="true">https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-to-participate-in-march-investor-conferences</guid>
      <pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
      <description>BEDFORD, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to</description>
    </item>
    <item>
      <title>Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations</title>
      <link>https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-to-present-detailed-sol-1-data-at-the-49th-macula-society-annual-meeting-and-host-investor-webcast-to-discuss-presentations</link>
      <guid isPermaLink="true">https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-to-present-detailed-sol-1-data-at-the-49th-macula-society-annual-meeting-and-host-investor-webcast-to-discuss-presentations</guid>
      <pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
      <description>Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ET) Company to</description>
    </item>
    <item>
      <title>Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD</title>
      <link>https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-reports-positive-results-from-landmark-sol-1-phase-3-superiority-trial-in-wet-amd</link>
      <guid isPermaLink="true">https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-reports-positive-results-from-landmark-sol-1-phase-3-superiority-trial-in-wet-amd</guid>
      <pubDate>Tue, 17 Feb 2026 12:00:00 GMT</pubDate>
      <description>First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF treatment Superiority primary endpoint met with 74.1% of subjects in the AXPAXLI™ arm maintaining vision at Week 36, a 17.5% risk difference (p=0.0006), compared to aflibercept (2 mg) arm 65.9% of subjects treated with AXPAXLI maintained vision at Week 52, a 21.1% risk difference (p&lt;0.0001), compared to aflibercept (2 mg) arm Rescue-free rates in the A</description>
    </item>
    <item>
      <title>Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026</title>
      <link>https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutix-announce-topline-data-220000262</link>
      <guid isPermaLink="true">https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutix-announce-topline-data-220000262</guid>
      <pubDate>Fri, 13 Feb 2026 22:00:00 GMT</pubDate>
      <description>Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented at the 49th Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will host a webcast to review the topline results of the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known</description>
    </item>
    <item>
      <title>Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights</title>
      <link>https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-reports-fourth-quarter-and-full-year-2025-financial-results-and</link>
      <guid isPermaLink="true">https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-reports-fourth-quarter-and-full-year-2025-financial-results-and</guid>
      <pubDate>Thu, 05 Feb 2026 05:00:00 GMT</pubDate>
      <description>SOL-1 Phase 3 superiority trial results remain masked to date SOL-1 data expected to be presented at the 49th Macula Society Annual Meeting Ocular plans to</description>
    </item>
    <item>
      <title>Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutix-reports-inducement-grant-210100148</link>
      <guid isPermaLink="true">https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutix-reports-inducement-grant-210100148</guid>
      <pubDate>Fri, 23 Jan 2026 21:01:00 GMT</pubDate>
      <description>BEDFORD, Mass., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to its newly appointed Global Chief Commercial Officer, David W. Robinson. The awards were approved by Ocular’s Board of Directors and were made as inducements material to Mr. Robinson’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Sto</description>
    </item>
    <item>
      <title>Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer</title>
      <link>https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-appoints-david-w-robinson-global-chief-commercial-officer-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-appoints-david-w-robinson-global-chief-commercial-officer-2026</guid>
      <pubDate>Wed, 21 Jan 2026 05:00:00 GMT</pubDate>
      <description>Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA® while at</description>
    </item>
    <item>
      <title>Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD</title>
      <link>https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-announces-plans-accelerate-nda-submission-timeline-axpaxlitm-wet</link>
      <guid isPermaLink="true">https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-announces-plans-accelerate-nda-submission-timeline-axpaxlitm-wet</guid>
      <pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
      <description>Ocular intends to submit AXPAXLI New Drug Application (NDA) for wet AMD shortly after year one data from SOL-1, if positive SOL-1 topline data remain on track</description>
    </item>
    <item>
      <title>Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR</title>
      <link>https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-announces-first-patient-randomized-helios-3-phase-3</link>
      <guid isPermaLink="true">https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-announces-first-patient-randomized-helios-3-phase-3</guid>
      <pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
      <description>First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI’s registrational program in non-proliferative diabetic retinopathy</description>
    </item>
    <item>
      <title>Ocular Therapeutix™ to Participate in November and December Investor Conferences</title>
      <link>https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-participate-november-and-december-investor-conferences-2025-11</link>
      <guid isPermaLink="true">https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-participate-november-and-december-investor-conferences-2025-11</guid>
      <pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
      <description>BEDFORD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to</description>
    </item>
    <item>
      <title>Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights</title>
      <link>https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-reports-third-quarter-2025-financial-results-and-business</link>
      <guid isPermaLink="true">https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-reports-third-quarter-2025-financial-results-and-business</guid>
      <pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
      <description>Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate</description>
    </item>
    <item>
      <title>Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R</title>
      <link>https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-achieves-target-randomization-555-subjects-sol-r-2025-11-04</link>
      <guid isPermaLink="true">https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-achieves-target-randomization-555-subjects-sol-r-2025-11-04</guid>
      <pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
      <description>SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials</description>
    </item>
    <item>
      <title>Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025</title>
      <link>https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-report-third-quarter-2025-financial-results-november-4-2025-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-report-third-quarter-2025-financial-results-november-4-2025-2025</guid>
      <pubDate>Tue, 28 Oct 2025 04:00:00 GMT</pubDate>
      <description>BEDFORD, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to</description>
    </item>
    <item>
      <title>Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences</title>
      <link>https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-participate-upcoming-scientific-conferences-2025-10-07</link>
      <guid isPermaLink="true">https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-participate-upcoming-scientific-conferences-2025-10-07</guid>
      <pubDate>Tue, 07 Oct 2025 04:00:00 GMT</pubDate>
      <description>BEDFORD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to</description>
    </item>
    <item>
      <title>Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock</title>
      <link>https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-announces-pricing-underwritten-offering-common-stock-2025-09-30</link>
      <guid isPermaLink="true">https://6ix.com/company/ocular-therapeutix-inc/news/ocular-therapeutixtm-announces-pricing-underwritten-offering-common-stock-2025-09-30</guid>
      <pubDate>Tue, 30 Sep 2025 04:00:00 GMT</pubDate>
      <description>BEDFORD, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq: OCUL) (“Ocular”, the “Company”), an integrated biopharmaceutical company</description>
    </item>
  </channel>
</rss>